What to know
- Presentation Day/Time: Friday, April 25, 10:55 am–12:20 pm
- Presenter: Sylvia Tangney, PhD, MPH, EIS officer assigned to the National Center for Immunization and Respiratory Diseases, Division of Bacterial Diseases
What did we do?
- To describe Group B Streptococcus (GBS) epidemiology in infants and pregnant and postpartum women, we analyzed active, population-based surveillance for invasive GBS disease across 10 U.S. sites during 2007–2022.
What did we find?
- We identified 2,005 early-onset disease (EOD) and 2,409 late-onset disease (LOD) infant cases and 526, 542, and 2,056 cases among pregnant, postpartum, and nonpregnant women, respectively.
- EOD incidence declined from 0.37 in 2007 to 0.22 in 2015 and stabilized during 2016–2022 (mean = 0.22).
- LOD incidence was stable during 2007–2015 (mean = 0.32) but declined to 0.23 during 2016–2022.
- In 2022, an estimated 630 EOD and 830 LOD cases occurred nationally.
- During 2007–2022, incidence among pregnant and postpartum women remained stable (mean: pregnant = 0.09; postpartum = 0.90). Compared with nonpregnant women, incidence among pregnant and postpartum women was 5-fold and 50-fold higher, respectively.
Why does it matter?
- Despite initial declines in EOD incidence and small declines in LOD incidence, infant GBS disease persists.
- Pregnant and postpartum women have elevated risk for GBS disease, compared with nonpregnant women.
- Maternal vaccines have potential as a GBS prevention strategy.
***This presentation has updated data that will be shared at the EIS Conference.
Abstract Category: Group B Strep, Maternal, Child, and Adolescent Health